20th Dec 2021 12:49
4basebio Plc - Director/PDMR Shareholding4basebio Plc - Director/PDMR Shareholding
PR Newswire
London, December 20
20 December 2021
4basebio plc(the "Company")Director’s Dealing
4basebio PLC (AIM: 4BB), the specialist life sciences group focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines, announces that, on 17 December 2021 and 20 December 2021, Heikki Lanckriet, chief executive officer, acquired in aggregate 2,500 ordinary shares on behalf of his wife at 650 pence per share.
As a result of the acquisition of ordinary shares, Heikki Lanckriet’s beneficial holding, including shares held by persons closely associated with him, comprises 1,248,953 ordinary shares representing 10.14 per cent. of the Company’s issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further enquiries, please contact:
| 4basebio plc | +44 (0)12 2396 7943 |
| Heikki Lanckriet, CEO | |
| Cairn Financial Advisers LLP (Nominated Adviser) | +44 (0)20 7213 0880 |
| Jo Turner / Sandy Jamieson | |
| finnCap Ltd (Broker) | +44 (0)20 7220 0500 |
| Geoff Nash/Richard Chambers/Charlotte Sutcliffe | |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
Details of the person discharging managerial responsibilities/person closely associated Name Heikki Lanckriet Reason for notification Position/Status Chief Executive Officer Initial notification/ Amendment Initial Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Name 4basebio plc LEI 213800E2DX9EAIUNCB30 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the financial instrument, type Ordinary Shares of instrument Identification Code ISIN: GB00BMCLYF79 Nature of the transaction Acquisition of ordinary shares Price(s) and volume(s) Volume(s) Price (p)17/12/2021 1,500 650p
20/12/2021 1,000 650p
Aggregated information - Aggregated Volume 2,500- Price650 pence per share
Date of the transaction 17/12/2021 and 20/12/2021 Place of the transaction London Stock Exchange, AIMRelated Shares:
4basebio Plc